POMDOCTOR LIMITED Announces Strategic Upgrade, Focusing on "AI + Medical-Grade Smart Wearables" to Build a New Ecosystem for Full-Cycle Chronic Disease Management

Pomdoctor (NASDAQ: POM) announced a strategic upgrade to focus on AI + medical-grade smart wearables for full-cycle chronic disease management, aiming to build a closed-loop ecosystem of hardware, data, algorithms and services.

Rhea-AI Summary

Pomdoctor (NASDAQ: POM) announced a strategic upgrade to focus on AI + medical-grade smart wearables for full-cycle chronic disease management, aiming to build a closed-loop ecosystem of hardware, data, algorithms and services.

The company cites a global chronic disease management market CAGR of 11.7% to 2034 and highlights China’s ~180 million people with chronic conditions as a core opportunity.

Argus Mar 13 session

+3.34% close to close Open Argus

Details

News Market Reaction – POM

On Mar 13, the day this news came out, POM closed 3.34% above the previous close.

Data tracked by StockTitan Argus for the Mar 13 session.

Key Figures

Global chronic disease mgmt market 2024: USD 6.2 billion Global chronic disease mgmt 2025: USD 6.9 billion Global chronic disease mgmt 2034: USD 18.8 billion +2 more

Global chronic disease mgmt market 2024

USD 6.2 billion

Market size cited from Global Market Insights

Global chronic disease mgmt 2025

USD 6.9 billion

Projected market size for 2025

Global chronic disease mgmt 2034

USD 18.8 billion

Projected market size for 2034

CAGR

11.7%

Global chronic disease management market 2025–2034

Chronic patients in China

approximately 180 million people

Population living with chronic conditions in China

Historical Context

5 past events · Latest: Feb 04

5 events

1. Feb 04

   Insurance integration

   24h Move

   -1.5%

   Expansion of online medical insurance integration across major Chinese cities.

2. Feb 02

   Nasdaq deficiency notice

   24h Move

   +5.2%

   Nasdaq notice for trading below the $1.00 minimum bid requirement.

3. Jan 16

   Pharma partnerships

   24h Move

   -1.7%

   New collaborations with domestic drug makers to grow internet hospital business.

4. Dec 03

   First-half results

   24h Move

   -3.5%

   Higher revenue and gross profit but ongoing net loss and limited cash.

5. Oct 10

   IPO over-allotment

   24h Move

   +1.1%

   Full exercise of underwriter’s over-allotment option, lifting total IPO proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

artificial intelligence, medical-grade smart wearable devices, full-cycle chronic disease management, evidence-based medicine, +2 more

6 terms

artificial intelligence technical

"core track of "artificial intelligence ("AI") + medical-grade smart wearables""

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

medical-grade smart wearable devices medical

"Developing a portfolio of medical-grade smart wearable devices capable of delivering"

Medical-grade smart wearable devices are body-worn gadgets—like advanced versions of fitness trackers—designed to measure health signals (heart rate, oxygen, glucose, etc.) with clinical accuracy and secure data handling, often meeting regulatory and quality standards. For investors they matter because higher accuracy and certification can enable medical use, reimbursement, and partnerships with healthcare providers, which translate into bigger markets, clearer revenue paths, and lower regulatory risk—similar to choosing certified equipment over hobbyist gear.

full-cycle chronic disease management medical

"AI") + medical-grade smart wearables + full-cycle chronic disease management""

Full-cycle chronic disease management is a coordinated, ongoing approach that covers prevention, diagnosis, treatment, monitoring and care coordination for long-term conditions like diabetes or heart disease. For investors it signals a business model focused on steady, repeatable revenue and potential cost savings—similar to a subscription car-maintenance plan that keeps patients healthy, reduces emergency costs and can scale across populations under value-based or insurance payment systems.

evidence-based medicine medical

"with evidence-based medicine serving as the foundational principle."

Evidence-based medicine is the practice of evaluating medical treatments and products using well-designed scientific studies and data, rather than tradition or intuition. For investors, it matters because treatments supported by solid evidence are more likely to gain regulatory approval, wider medical adoption, reliable pricing and insurance coverage, and lower legal risk — think of it as choosing a product backed by a tested recipe rather than a guess.

clinical treatment guidelines medical

"grounded in established clinical treatment guidelines, the system is designed"

Clinical treatment guidelines are systematically developed recommendations that tell doctors which treatments, tests, or care steps work best for specific medical conditions—like a tested recipe or roadmap for patient care. They matter to investors because guidelines shape how widely and quickly a drug, device, or test will be used, influence reimbursement and regulatory acceptance, and therefore affect market size, sales forecasts, and competitive positioning.

internet hospital platform technical

"integrates hardware terminals and AI systems with the Company's existing internet hospital platform"

An internet hospital platform is an online system that connects patients with licensed clinicians, pharmacies, and medical records to deliver consultations, prescriptions, tests and follow-up care remotely — like a virtual clinic you can access from a phone or computer. Investors care because these platforms can scale patient volume quickly, create recurring revenue streams, and face regulatory and reimbursement risks that affect growth and profitability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GUANGZHOU, China, March 13, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced a strategic upgrade centered on the core track of "artificial intelligence ("AI") + medical-grade smart wearables + full-cycle chronic disease management".

The Company plans to accelerate related technology research and development ("R&D") and scenario-based implementation by leveraging its extensive medical resources and strong compliance capabilities. Over the long run, Pomdoctor aims to build a closed-loop chronic disease management ecosystem integrating hardware, data, algorithms and services, expanding the Company's long-term growth horizon while delivering sustained medical value to patients.

According to Global Market Insights, the global chronic disease management market was valued at USD 6.2 billion in 2024 and is projected to grow from USD 6.9 billion in 2025 to USD 18.8 billion by 2034, representing a compound annual growth rate (CAGR) of 11.7%. In China, driven by an aging population and approximately 180 million people living with chronic conditions, the country has emerged as one of the world's largest and most promising markets for chronic disease management technologies and services.

Against this backdrop, traditional outpatient-based chronic disease management continues to face structural challenges, including fragmented monitoring, delayed medical intervention, and low patient adherence. The broader adoption of smart wearable technologies and emerging AI applications is now beginning to reshape the landscape, pointing toward a new paradigm for digital healthcare.

According to Pomdoctor, this strategic upgrade represents a natural extension of the Company's longstanding expertise and operational experience in chronic disease management, rather than a cross-industry expansion without prior validation. All R&D and commercialization activities will strictly comply with applicable medical regulatory requirements in both China and the United States, with evidence-based medicine serving as the foundational principle.

The strategic upgrade will focus on three core areas of compliant implementation:

• Developing a portfolio of medical-grade smart wearable devices capable of delivering accurate and continuous physiological data to support chronic disease management, particularly for high-prevalence conditions such as diabetes and cardiovascular diseases;
• Building an AI-powered intelligent chronic disease management system. Leveraging health data collected from wearable devices and grounded in established clinical treatment guidelines, the system is designed to function as an intelligent assistant for risk monitoring, treatment plan support, and doctor-patient collaboration, ultimately improving management efficiency and patient adherence to outpatient care;
• Establishing a closed-loop chronic disease management service system that integrates hardware terminals and AI systems with the Company's existing internet hospital platform, pharmaceutical supply chain, and chronic disease service infrastructure, enabling full-cycle services from monitoring and early warning to intervention and follow-up.

The Company plans to support this strategic transformation through three core competitive advantages:

• A strong medical compliance foundation: established internet hospital qualifications, a nationwide network of licensed physicians, and a comprehensive compliance management system supported by deep understanding of clinical needs and regulatory frameworks;
• Collaborative R&D capabilities: a multidisciplinary team of algorithm experts, hardware engineers, and clinical medicine specialists to ensure close alignment between technological innovation and real-world clinical requirements;
• Advantages as a U.S.-listed company: a standardized corporate governance structure, global resource integration capabilities, and stable capital access to support technology R&D, clinical validation, and international commercialization.

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "The integration of AI and medical-grade wearable technologies is reshaping the paradigm of chronic disease management. Through this strategic upgrade, we will steadily advance technology R&D and real-world implementation to develop clinically meaningful chronic disease management solutions. This strategic direction reflects our unwavering commitment to medical compliance and patient-centered care. We believe this transformation aligns with the long-term evolution of the healthcare industry and will generate sustainable value for both patients and our shareholders."

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-strategic-upgrade-focusing-on-ai--medical-grade-smart-wearables-to-build-a-new-ecosystem-for-full-cycle-chronic-disease-management-302712134.html

SOURCE POMDOCTOR LIMITED

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Pomdoctor's strategic upgrade announced March 13, 2026 (POM)?

Pomdoctor is shifting to an integrated model of AI + medical-grade wearables for chronic disease care. According to Pomdoctor, the plan builds a closed-loop ecosystem combining devices, algorithms, data and services to support monitoring, intervention and follow-up.

How big is the market opportunity Pomdoctor cites for chronic disease management (POM)?

The company highlights a large market, citing a global market CAGR of 11.7% to 2034. According to Pomdoctor, the global market was valued at USD 6.2 billion in 2024, with strong growth driven by China’s ~180 million chronic patients.

What product and system development will Pomdoctor pursue under the POM strategic plan?

Pomdoctor plans to develop medical-grade wearable devices and an AI-powered chronic disease management system. According to Pomdoctor, the system will use continuous physiological data and clinical guidelines to support risk monitoring and treatment-plan collaboration.

How will regulatory compliance factor into Pomdoctor's AI and wearable strategy (POM)?

Pomdoctor commits to strict compliance with medical regulations in China and the U.S. According to Pomdoctor, all R&D and commercialization activities will follow applicable regulatory requirements and be grounded in evidence-based medicine.

What advantages does Pomdoctor (POM) cite to support this strategic upgrade?

Pomdoctor cites a nationwide licensed physician network, multidisciplinary R&D capabilities, and U.S. listing benefits for governance and capital access. According to Pomdoctor, these strengths will support clinical validation, technology R&D, and international commercialization.